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Abstract
Background: Hyperglycemia-induced changes in vascular wall structure contribute to the
pathogenesis of diabetic microvascular and macrovascular complications. Matrix
metalloproteinases (MMP), a family of proteolytic enzymes that degrade extracellular matrix (ECM)
proteins, are essential for vascular remodeling. We have shown that endothelin-1 (ET-1) mediates
increased MMP activity and associated vascular remodeling in Type 2 diabetes. However, the effect
of Type 2 diabetes and/or ET-1 on the regulation of ECM and MMP gene expression in different
vascular beds remains unknown.
Methods: Aorta and mesenteric artery samples were isolated from control, Type 2 diabetic Goto-
Kakizaki (GK) rats and GK rats treated with ETA antagonist ABT-627. Gene expression profile of
MMP-2, MMP-9, MT1-MMP, fibronectin, procollagen type 1, c-fos and c-jun, were determined by
quantitative real-time (qRT) PCR. In addition, aortic gene expression profile was evaluated by an
ECM & Adhesion Molecules pathway specific microarray approach.
Results: Analysis of the qRT-PCR data demonstrated a significant increase in mRNA levels of
MMPs and ECM proteins as compared to control animals after 6 weeks of mild diabetes.
Futhermore, these changes were comparable in aorta and mesentery samples. In contrast,
treatment with ETA antagonist prevented diabetes-induced changes in expression of MMPs and
procollagen type 1 in mesenteric arteries but not in aorta. Microaarray analysis provided evidence
that 27 extracellular matrix genes were differentially regulated in diabetes. Further qRT-PCR with
selected 7 genes confirmed the microarray data.
Conclusion: These results suggest that the expression of both matrix scaffold protein and matrix
degrading MMP genes are altered in macro and microvascular beds in Type 2 diabetes. ETA
antagonism restores the changes in gene expression in the mesenteric bed but not in aorta
suggesting that ET-1 differentially regulates microvascular gene expression in Type 2 diabetes.
Introduction
Changes in vascular wall structure occur in diabetes and
contribute to both micro- and macrovascular complica-
tions. Previous studies in streptozosin (STZ)-induced
model of Type 1 diabetes documented increased intimal
proliferation and medial thickness as well as extracellular
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mesenteric arteries as early as 3 weeks of experimental dia-
betes [1-4]. Vascular remodeling and hypertrophy associ-
ated with augmented expression of dedifferentiation
markers of vascular smooth muscle cells also occur in
larger vessels like aorta [5]. While these studies provided
evidence for diabetes-induced alterations in ECM synthe-
sis and vascular structure of an experimental model of
Type 1 diabetes that is characterized by highly elevated
blood glucose levels, to what extent mild-to-modest
hyperglycemia as seen in Type 2 diabetes influences the
gene expression of ECM proteins associated with vascular
remodeling and whether there are differences in micro vs
macrovascular bed are not fully understood.
Vascular ECM proteins such as collagen type 1 and 3,
fibronectin and thrombospondins not only function as
scaffolding proteins but also involved in matrix signaling
by interacting with integrin family of proteins and trigger-
ing growth-promoting signals. ECM displays a very
dynamic equilibrium where there is constant synthesis,
degradation and reorganization. Turnover of matrix pro-
teins are regulated by matrix metalloproteinases (MMPs)
[6]. While decreased MMP activity is generally believed to
contribute to ECM accumulation in diabetic kidney and
in vascular tissue from patients with diabetes, we and oth-
ers have recently reported that there is an early activation
of MMPs in hypertension and diabetes [7-9]. However,
transcriptional regulation of ECM proteins and MMPs in
different vascular beds and specifically in Type 2 diabetes
remains to be determined.
Vasoactive factors including endothelin-1 (ET-1) and
angiotensin II are involved in diabetic vascular remode-
ling as evidenced by studies that demonstrated attenua-
tion of these responses by blockade of these systems in
both experimental and clinical diabetes. For example, Gil-
bert and colleagues reported that ETA receptor antagonism
prevents mesenteric vascular hypertrophy in Type 1 diabe-
tes [4]. Another study provided evidence that blockade of
ET-1 action inhibits ECM deposition in the aorta as well
[5]. We recently reported that ET-1 levels are elevated and
an ETA antagonist prevents ECM deposition and MMP
activation in middle cerebral arteries but not in the kidney
of Goto-Kakizaki (GK) rats, a non-obese Type 2 diabetes
model [9,10]. Thus, this study was designed to test the
hypothesis that there is a differential regulation of MMP
activation in micro vs macrovessels in Type 2 diabetes and
ET-1 contributes to this process.
Methods
Animal and tissue preparation
All experiments were performed on male Wistar (Harlan,
Indianapolis, IN) and Goto-Kakizaki (in-house bred,
derived from the Tampa colony) rats [11]. The animals
were housed at the Medical College of Georgia animal
care facility that is approved by the American Association
for Accreditation of Laboratory Animal Care and study
was approved by the Institutional Animal Care and Use
Committee. Animals were fed standard rat chow and tap
water ad-libitum. During housing, drinking water meas-
urements, weight, and blood glucose measurements were
performed twice weekly. At 12 weeks of age, when all GK
animals became overtly diabetic, telemetry transmitters
for blood pressure measurements were implanted as pre-
viously reported [12]. After a 2 week-recovery period, con-
trol and diabetic animals were administered the ETA
selective antagonist, ABT-627 (5 mg/kg/day) in drinking
water, or vehicle only [8]. Treatment was maintained until
the time of sacrifice at 18 weeks of age. Animals were anes-
thetized with sodium pentobarbital and exsanguinated
via the abdominal aorta. Upon sacrifice, the mesenteric
Table 1: List of primers used in qRT-PCR
Primer ID Accession No Sequence Expect Size (bp)
MMP-9 (F) NM_031055 GTC TTC CCC TTC GTC TTC CT 117
MMP-9 (R) ACC CCA CTT CTT GTC AGC GT
MMP-14 (F) NM_031056 TGT CCC AGA TAA GCC CAG AA 128
MMP-14 (R) TAT TCC TCA CCC GCC AGA AC
GAPDH (F) XM_234433 AGC CCA GAA CAC CAT TCC TAC 191
GAPDH (R) ATG CCT GCT TCA CCA CAT TC
FIBRONECTIN (F) X15906 GCA CAG GGG AAG AAA AGG AG 189
FIBRONECTIN (R) TTG AGT GGA TGG GAG GAG AG
MMP-2 (F) NM_031054 GTG CCA AGG TGG AAA TCA GAG 110
MMP-2 (R) AAG GTT GAA GGA AAC GAG CGA
Procollagen 1 (F) Z78279 AAG GGT GAG ACA GGC GAA CAA 170
Procollagen 1 (R) TTG CCA GGA GAA CCA GCA GAG
c-fos (F) XM_234422 GTG GTG GAA GGC GTA TCG AGT TT 102
c-fos (R) GTG TGA TGC CAG AAG CAG ATC CA
c-jun (F) X17163 CCT AGC TGA ACT GCA TAG CCA GAA 177
c-jun (R) AAG TTG CTG AGG TTG GCG TAG APage 2 of 7
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thoracic aorta were isolated and immediately put into
RNAlater™ (Ambion, Austin, TX, USA) for storage at -
80°C.
RNA isolation and cDNA synthesis
Total RNA extraction was carried out using the RNeasy®
Mini kit (Qiagen Inc., Valencia, CA) according to manu-
facturer's instructions. RNA quality from each sample was
assured by the A260/280 absorbance ratio and by electro-
phoresis of 1.2% agarose formaldehyde gel. 1.0–2.0 µg of
total RNA was reverse transcribed into single strand cDNA
using MuLV reverse transcriptase (Applied Biosystems,
Foster City, CA, USA). RT reaction was carried out for 60
min at 42°C and 5 min at 95°C in a thermocycler.
Primer design and qRT-PCR
All oligonucleotide primer sets were designed based upon
published mRNA sequence. Expected amplicon lengths
were from 100 bp – 200 bp. Oligonucleotide primers used
in this study are listed in Table 1. The qRT-PCR was per-
formed in a SmartCycler II (Cepheid, Sunnyvale, CA) by
using SYBR® Green PCR Master Mix (Applied Biosystems,
Foster City, CA, USA). 2–2.5 µl of cDNA template was
used for qRT-PCR in a final volume of 25 µl. cDNA was
amplified according to the following condition: 95°C for
15 s and 60°C for 60 s from 40 to 45 amplification cycles.
Fluorescence changes were monitored with SYBR Green
after every cycle. Melting curve analysis was performed
(0.5°C/s increase from 55–95°C with continuous fluores-
cence readings) at the end of cycles to ensure that single
PCR products were obtained. Amplicon size and reaction
specificity were confirmed by 2.5% agarose gel electro-
phoresis. All reactions were repeated in 3 separate PCR
runs using RNA isolated from 3 sets of animals. Results
were evaluated with the SmartCycler II software. Glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) primers
were used to normalize samples. To monitor crossover
contaminations of PCR, RNase-free water (Qiagen Inc.,
Valencia, CA) was included in the RNA extraction and
used as a negative control. To ensure quality of data, a neg-
ative control was always applied in each run.
cDNA gene expression array analysis
The expression profile of extracellular matrix & adhesion
molecules genes was analyzed using the non-radioactive
GEArray Q series Mouse gene array (MM-010N, SuperAr-
ray Bioscience Corp., Frederick, MD). This array mem-
brane is composed of 96 extracellular matrix & adhesion
molecules genes, a plasmid pUC18 negative control, and
four housekeeping genes including glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), cyclophilin A,
ribosomal protein L13a, and β-actin. Biotinylated cDNA
probes were denatured and hybridized to extracellular
matrix & adhesion molecules gene-specific cDNA frag-
ments spotted on the membranes. After pre-hybridization
with GEAhyb Hybridization Solution (SuperArray) of
denatured salmon sperm DNA (Invitrogen). The array
membrane was hybridized with denatured cDNA probes
overnight at 55°C. Following washing the membrane
twice with 2 × SSC, 1% SDS and twice with 0.1 × SSC,
0.5% SDS for 15 min at 55°C each, the membrane was
blocked with GEAblocking Solution Q (SuperArray) for
40 min and incubated with alkaline phosphatase-conju-
gated streptavidin for 10 min at room temperature.
Chemiluminescent detection was performed using CDP-
Table 3: qRT-PCR-based fold changes in gene expression in control vs diabetic GK rats treated with or without ABT-627.
Aorta Mesenteric artery
C vs GK GK vs GK+ABT627 C vs GK GK vs GK+ABT627
MMP-2 ↑10* No change ↑11* ↓3**
MMP-9 ↑3* No change ↑10* ↓2**
MT1-MMP ↑6* No change ↑7* ↓7**
COL1A1 ↑27* No change ↑7* ↓8**
Fibronectin ↑1.23 ↓1.25 ↑9* ↓3**
c-Fos ↓3* ↑2 ↓3* ↑2**
c-Jun ↑3* No change ↑3* ↓5**
* p < 0.05 C vs GK, **p < 0.05 GK vs GK+ABT-627
Table 2: Metabolic parameters of Control Wistar and GK rats.
Metabolic Parameters Control GK GK + ABT-627
Body weight (g) 502 ± 11 359 ± 7* 379 ± 29
Blood glucose (mg/dl) 116 ± 5 239 ± 23* 211 ± 18
Mean Arterial Pressure (MAP, mm Hg) 101 ± 2 110 ± 7 112 ± 1
*P < 0.05 vs controlPage 3 of 7
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qRT-PCR analysis of diabetes-induced alterations in ECM and MMP expressionFigure 1













































































Cardiovascular Diabetology 2006, 5:3 http://www.cardiab.com/content/5/1/3Star substrate. The results were analyzed with ScanAlyze
and GEArray Analyzer. The relative expression levels of
different genes were estimated by comparing its signal
intensity with that of internal control β-actin.
Data analysis
RT-PCR results were reported as relative gene expression
and the fold change in target genes was determined by 2-
∆∆Ct method, where -∆∆Ct = (CtTarget - CtActin)GK - (CtTarget -
CtActin)control and Ct value = the cycle number that crosses
signal threshold. To evaluate the effect of ABT-627 treat-
ment on gene expression profile in the diabetic group,
fold change was determined as (CtTarget - CtActin)GK - (CtTarget
- CtActin)GK + ABT-627. Group comparisons (C vs GK or GK vs
GK +ABT-627) were performed using Student's t-test. For
Array studies, relative gene expression was analyzed using
the SAM (Statistical Analysis of Microarrays) software
[13].
Results and discussion
GK rats displayed mildly elevated blood glucose levels
that are representative of blood glucose levels seen in
patients with Type 2 diabetes (Table 2). There were no sig-
nificant changes in blood pressure and lipid profile. We
have previously shown that GK rats are hypoinsulinemic
and display impaired glucose tolerance. Euglycemic
hyperinsulinemic clamp studies indicated that GK rats are
also insulin resistant. These results strongly suggest that
insulin resistance in GKs worsens impaired insulin secre-
tion and leads to hypoinsulinemia as seen in a majority of
patients with Type 2 diabetes that eventually become
insulin-dependent and thus represent a clinically relevant
model.
Since MMP-2, MMP-9 and MT1-MMP are major MMP
species found in the vasculature and our previous studies
suggested time-dependent differential regulation of
MMPs in diabetes [8,9,14-16], we first studied MMP and
collagen gene expression in aorta and mesentery samples
obtained from control and GK rats. Results summarized
in Figure 1 demonstrated that mild elevation of blood glu-
cose for 6 weeks is sufficient to stimulate gene expression
of MMP-2, MMP-9 and MT1-MMP in both aorta and
mesentery samples to a similar degree. Interestingly, col-
lagen type 1 expression was higher in the aortic samples
than in mesenteric vessels of diabetic animals. Fibronectin
expression was unchanged in aorta but significantly
increased in the mesentery. c-jun expression, which is
involved in early growth response, was also increased
whereas c-fos expression was lower in the diabetic group.
To the best of our knowledge, these results are first to
demonstrate increased MMP gene expression in small
mesenteric arteries and in aorta in diabetes. We have
recently reported that MMP protein and activity is
increased in the middle cerebral arteries of GK rats and
this is associated with vascular remodeling characterized
by increased medial thickness and decreased
lumen:media ratio [9]. Current findings strongly suggest
that changes in enzyme activity parallel changes in gene
expression indicating stimulation of the MMP system at
transcriptional level in Type 2 diabetes. Our results are
consistent with the previous reports that showed
increased collagen expression in the mesenteric bed in
Type 1 diabetes and further demonstrate that this increase
is to a greater extent in large muscular vessels [4,17,18].
Our findings on fibronectin expression in aorta, however,
differ from a recent report by Fukuda et al, who demon-
strated a 4-fold increase in aortic fibronectin expression
[5]. This difference may be attributed to the use of a model
of Type 1 diabetes or the time point (26 weeks after the
induction of diabetes) at which collagen expression was
evaluated.
The role of local vasoactive factors in diabetic vascular
remodeling has been an active area of research. Given that
hyperglycemia stimulates the production of ET-1, the
most potent vasoconstrictor with mitogenic and profi-
brotic properties, prompted studies with ET receptor
antagonists to identify the involvement of the ET system
in diabetic vascular complications [4,19-21]. However, a
big majority of these studies were conducted using exper-
imental models of Type 1 diabetes or obese animals. We
have recently shown that ET-1 levels are elevated in the
GK model [9]. Thus, the current study investigated the
role of endogenous ET-1 on micro and macrovascular
gene expression in the GK model. Results summarized in
Table 3 demonstrate that blockade of the ETA receptor
subtype early in the disease process does not prevent dia-
betes-induced increases in the expression of ECM proteins
and MMPs in aorta. However, ET receptor antagonism
completely attenuates increases in MT1-MMP and colla-
A representative image of extracellular matrix and adhesion molecular microarray of control and GK ratsFigure 2
A representative image of extracellular matrix and adhesion 
molecular microarray of control and GK rats.
Control GKPage 5 of 7
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MMP-2, MMP-9 and fibronectin expression. These novel
findings suggest that there is differential regulation of
microvascular ECM gene expression in Type 2 diabetes.
Our results confirm the findings of Gilbert et al. that ETA
receptor blockade prevents microvascular hypertrophy in
Type 1 diabetes and extends these results to Type 2 diabe-
tes [4].
In order to determine whether expression of other ECM
proteins is altered in the GK model, aortic gene expression
profile was investigated using an ECM and Adhesion Mol-
ecules pathway specific microarray approach (Fig. 2).
Genes that showed a significant change in the expression
(p < 0.05 vs control) were grouped as adhesion molecules,
ECM proteins and proteases in Table 4 and demonstrated
that a total of 27 genes out of 96 genes were differentially
regulated in GK rats. There were significant increases in
various integrins and MMPs confirming our qRT-PCR
results. Increased expression of adhesion molecules is
important in diabetes not only to facilitate the adhesion
and penetration of inflammatory cells but also to transmit
the ECM-generated signals to underlying smooth muscle
cells. We observed decreases in thrombospondin-2 (TSP-
2) but increases in TSP-3 and -4 expression and no change
in TSP-1. These results are particularly interesting with
regard to the interaction of TSP-2 with MMP and other
ECM proteins [22-24]. TSP-2 belongs to an extracellular
glycoprotein family and it is involved in cell-matrix inter-
actions including inhibition of MMP-2 by binding to the
active protein as well as decreasing MMP expression [24-
26]. TSP-2 knock-out mice display defects in collagen
fibril formation and attachment to ECM proteins. In this
study we observed decreased TSP-2 and increased MMP-2
activation. Thus, it is reasonable to speculate that
decreased TSP-2 expression may contribute to increased
MMP-2 activation and decreased cell-matrix attachment
resulting in a more free environment for vascular smooth
muscle cells to migrate and remodel in diabetes. However,
it has to be recognized that current studies involve only
gene expression of ECM proteins and should be extended
to the protein/activity level to be more definitive.
In conclusion, mild diabetes can stimulate a gene expres-
sion pattern that promotes remodeling of both micro and
macrovessels. While ET-1 contributes to the alterations in
gene expression profile in the microvasculature via activa-
tion of the ETA receptor subtype, changes in macrovascular
gene expression are independent of ET-1.
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